Protagonist Therapeutics (PTGX) Fundamentals 2026 — Revenue Analysis | SniperIQ

35.00 on the NASDAQ. This SniperIQ fundamentals page covers Protagonist Therapeutics's valuation, profitability (net margin -154.9%), revenue ($46M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Protagonist Therapeutics's market cap?

Protagonist Therapeutics (PTGX) has a market capitalization of approximately $8.7B, trading at

35.00 on the NASDAQ. Market cap moves with the live share price.

What is Protagonist Therapeutics's P/E ratio?

Protagonist Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 13.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Protagonist Therapeutics?

Protagonist Therapeutics runs a net profit margin of -154.9%, a gross margin of 99.5%, and an operating margin of -192.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Protagonist Therapeutics generate?

Protagonist Therapeutics reported revenue of $46M for fiscal year 2025, with net income of -

30M and earnings per share (EPS) of -2.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Protagonist Therapeutics pay a dividend?

Protagonist Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Protagonist Therapeutics financially healthy?

Protagonist Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 17.76x, with a market beta of 1.79. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Protagonist Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Protagonist Therapeutics (PTGX) the key facts are: market cap $8.7B, revenue $46M, 52-week range 50.485-143.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.